Clinical Trial Update: Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso [Phase 1]

View source ↗

Summary

A Phase 1 safety trial testing age de-escalation of the PfSPZ-LARC2 malaria vaccine in Burkina Faso has completed, sponsored by Sanaria Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• PfSPZ-LARC2

Snippet

Sponsor: Sanaria Inc. | Conditions: Malaria Falciparum, Malaria Infection | Phase 1 | Status: COMPLETED